Zuranolone: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Create Zuranolone page (Stahl-sourced detail with skepticism) |
MDElliottMD (talk | contribs) Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name) |
||
| Line 14: | Line 14: | ||
| pregnancy = Limited data; avoid in pregnancy. Lactation: present in milk; consider risks | | pregnancy = Limited data; avoid in pregnancy. Lactation: present in milk; consider risks | ||
| legal = Rx, Schedule IV (US) | | legal = Rx, Schedule IV (US) | ||
| intro = '''Zuranolone''' (brand name Zurzuvae) is the first '''oral''' neuroactive steroid approved for postpartum depression, FDA-approved in August 2023. Like brexanolone, it acts as a positive allosteric modulator at GABA-A receptors, including extrasynaptic δ-containing subtypes thought to mediate antidepressant effect. Administered as a 14-day fixed-duration course rather than chronic daily dosing — an unusual paradigm in psychiatry. Initially studied for major depressive disorder (MDD) as well but the MDD application was rejected by FDA; only PPD | | intro = '''Zuranolone''' (brand name Zurzuvae) is the first '''oral''' neuroactive steroid approved for postpartum depression, FDA-approved in August 2023. Like brexanolone, it acts as a positive allosteric modulator at GABA-A receptors, including extrasynaptic δ-containing subtypes thought to mediate antidepressant effect. Administered as a 14-day fixed-duration course rather than chronic daily dosing — an unusual paradigm in psychiatry. Initially studied for major depressive disorder (MDD) as well but the MDD application was rejected by FDA; only PPD problem approved. | ||
| pharmacodynamics= Positive allosteric modulator at synaptic and extrasynaptic GABA-A receptors at the neuroactive steroid binding site, with affinity for δ-containing extrasynaptic receptors. Oral bioavailability with food enables outpatient dosing, unlike brexanolone's IV infusion. | | pharmacodynamics= Positive allosteric modulator at synaptic and extrasynaptic GABA-A receptors at the neuroactive steroid binding site, with affinity for δ-containing extrasynaptic receptors. Oral bioavailability with food enables outpatient dosing, unlike brexanolone's IV infusion. | ||
| effects = Somnolence (most common, can affect driving — black-box warning about CNS depressant activities for ≥12 hours after dose), dizziness, sedation, headache, diarrhea, fatigue. Suicidal thoughts reported. | | effects = Somnolence (most common, can affect driving — black-box warning about CNS depressant activities for ≥12 hours after dose), dizziness, sedation, headache, diarrhea, fatigue. Suicidal thoughts reported. | ||
Revision as of 01:37, 19 May 2026
Neuroactive steroid, GABA-A positive allosteric modulator (oral)
Zuranolone
Zurzuvae
Zuranolone (brand name Zurzuvae) is the first oral neuroactive steroid approved for postpartum depression, FDA-approved in August 2023. Like brexanolone, it acts as a positive allosteric modulator at GABA-A receptors, including extrasynaptic δ-containing subtypes thought to mediate antidepressant effect. Administered as a 14-day fixed-duration course rather than chronic daily dosing — an unusual paradigm in psychiatry. Initially studied for major depressive disorder (MDD) as well but the MDD application was rejected by FDA; only PPD problem approved.
Positive allosteric modulator at synaptic and extrasynaptic GABA-A receptors at the neuroactive steroid binding site, with affinity for δ-containing extrasynaptic receptors. Oral bioavailability with food enables outpatient dosing, unlike brexanolone's IV infusion.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
Somnolence (most common, can affect driving — black-box warning about CNS depressant activities for ≥12 hours after dose), dizziness, sedation, headache, diarrhea, fatigue. Suicidal thoughts reported.
Pharmacodynamics
Interactions
Fluoxetine via Category:Antidepressants exp n/a/5 outcome n/a (n=1) exp 1.0/5 outcome +33.0 (n=1)
How much experience do you have with this combination (1 a little, 5 a lot)?
How did it go? (-100 worst, +100 best)
- checking this mechanism here
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Neuroactive steroid, GABA-A positive allosteric modulator (oral)
Common uses
Postpartum depression (PPD) in adults (FDA-approved 2023)
Pharmacy
Starting dose
50 mg PO once daily with fatty food in the evening × 14 days
Preparations
20 mg, 25 mg, 30 mg capsules
US FDA Max
50 mg/d × 14 d
Pharmacology
Routes
Oral
Onset
Day 3 of dosing in trials; sustained through day 45
Duration
14-day course; effect persists after discontinuation in trials
Half-life
~16-23 hours
Bioavailability
Adequate (food-dependent — must take with fatty meal)
Pregnancy
Limited data; avoid in pregnancy. Lactation: present in milk; consider risks
Legal status
Rx, Schedule IV (US)
Purported mechanism
Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes.